ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
A Meta-Analysis of Placebo Controlled Testosterone Studies Finds TRT Safe
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 30042" data-attributes="member: 3"><p><strong>Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials</strong></p><p></p><p></p><p>Abstract</p><p></p><p>The purpose of the present meta-analysis was to evaluate the efficacy and safety of testosterone replacement therapy in men with hypogonadism. A search was conducted for appropriate randomized controlled trials and the data from 16 trials were pooled. The intended primary outcome of the present study was to determine the efficacy and safety of testosterone replacement therapy. The current data demonstrated that scores for Aging Male Symptoms (AMS) were significantly reduced following testosterone replacement therapy, with a mean decrease in AMS score of 1.52 [95% confidence interval (CI), 0.72 to 2.32; P=0.0002]. Testosterone replacement therapy increased lean body mass [mean difference (MD), 1.22; 95% CI, 0.33 to 2.11; P=0.007], reduced fat mass in a non&#8209;significantly manner (MD, &#8209;0.85; 95% CI, &#8209;1.74 to 0.04; P=0.06) and significantly reduced total cholesterol (MD, &#8209;0.16; 95% CI, &#8209;0.29 to &#8209;0.03; P=0.01). No significant differences were identified in body weight (MD, 0.09; 95% CI, &#8209;1.13 to 1.31; P=0.89), body mass index (MD, 0.10; 95% CI, &#8209;0.62 to 0.82; P=0.78) or bone mineral density (MD, &#8209;0.01; 95% CI, &#8209;0.03 to 0.02; P=0.60). Average prostate volume increased (MD, 1.58; 95% CI, 0.6 to 2.56; P=0.002) following testosterone replacement therapy, but the levels of prostate&#8209;specific antigen (PSA) (MD, 0.10; 95% CI, &#8209;0.03 to 0.22; P=0.14) and the International Prostate Symptom Scores (MD, 0.01; 95% CI, &#8209;0.37 to 0.39; P=0.96) did not change. In conclusion, testosterone replacement therapy improves quality of life, increases lean body mass, significantly decreases total cholesterol, and is well&#8209;tolerated and safe for men with hypogonadism who are exhibiting PSA levels of <4 ng/ml.</p><p></p><p></p><p>[ATTACH]1711[/ATTACH]</p><p></p><p></p><p>Reference:</p><p>Guo, C., Gu, W., Liu, M., Peng, B., Yao, X., Yang, B., Zheng, J."Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials". Experimental and Therapeutic Medicine 0, no. 0 (1899): 0-0. </p><p></p><p></p><p>Paper attached</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 30042, member: 3"] [B]Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials[/B] Abstract The purpose of the present meta-analysis was to evaluate the efficacy and safety of testosterone replacement therapy in men with hypogonadism. A search was conducted for appropriate randomized controlled trials and the data from 16 trials were pooled. The intended primary outcome of the present study was to determine the efficacy and safety of testosterone replacement therapy. The current data demonstrated that scores for Aging Male Symptoms (AMS) were significantly reduced following testosterone replacement therapy, with a mean decrease in AMS score of 1.52 [95% confidence interval (CI), 0.72 to 2.32; P=0.0002]. Testosterone replacement therapy increased lean body mass [mean difference (MD), 1.22; 95% CI, 0.33 to 2.11; P=0.007], reduced fat mass in a non‑significantly manner (MD, ‑0.85; 95% CI, ‑1.74 to 0.04; P=0.06) and significantly reduced total cholesterol (MD, ‑0.16; 95% CI, ‑0.29 to ‑0.03; P=0.01). No significant differences were identified in body weight (MD, 0.09; 95% CI, ‑1.13 to 1.31; P=0.89), body mass index (MD, 0.10; 95% CI, ‑0.62 to 0.82; P=0.78) or bone mineral density (MD, ‑0.01; 95% CI, ‑0.03 to 0.02; P=0.60). Average prostate volume increased (MD, 1.58; 95% CI, 0.6 to 2.56; P=0.002) following testosterone replacement therapy, but the levels of prostate‑specific antigen (PSA) (MD, 0.10; 95% CI, ‑0.03 to 0.22; P=0.14) and the International Prostate Symptom Scores (MD, 0.01; 95% CI, ‑0.37 to 0.39; P=0.96) did not change. In conclusion, testosterone replacement therapy improves quality of life, increases lean body mass, significantly decreases total cholesterol, and is well‑tolerated and safe for men with hypogonadism who are exhibiting PSA levels of <4 ng/ml. [ATTACH=CONFIG]1711[/ATTACH] Reference: Guo, C., Gu, W., Liu, M., Peng, B., Yao, X., Yang, B., Zheng, J."Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials". Experimental and Therapeutic Medicine 0, no. 0 (1899): 0-0. Paper attached [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
A Meta-Analysis of Placebo Controlled Testosterone Studies Finds TRT Safe
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top